Business Context and Reporting Period
NextCure, Inc. filed a Form 8-K dated September 21, 2026, reporting a Delaware Court of Chancery proceeding concerning the validity of its 2025 reverse stock split. The filing was signed September 25, 2026. NextCure is also pursuing a proposed business combination with Avere Therapeutics, Inc.
Material Legal and Corporate Developments
- On September 14, 2026, NextCure filed a petition under Section 205 of the Delaware General Corporation Law seeking validation of its July 10, 2025 certificate amendment and all shares issued in reliance on that amendment.
- The amendment authorized a reverse stock split at a ratio between 1-for-5 and 1-for-15. The board selected a 1-for-12 split, which became effective July 10, 2025.
- At the June 20, 2025 annual meeting, the proposal received 18,166,577 votes for, 2,028,946 against and 6,613 abstentions. The company reported support of approximately 89.92% of votes cast and 64.76% of outstanding shares entitled to vote.
- NextCure applied a votes-cast standard based on its interpretation of then-effective Delaware law. Following amendments to the relevant Delaware statute in August 2026, the company identified uncertainty over whether a supermajority standard should have applied.
- The Court of Chancery ordered an expedited hearing for November 6, 2026, at 3:00 p.m. Eastern Time in Wilmington, Delaware.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating guidance or other financial metrics. The filing text does not provide a clear value for any such measures.
Guidance, Outlook, Risks and Contingencies
- The outcome of the Section 205 action is uncertain. An unfavorable outcome could adversely affect NextCure, including by delaying or preventing the proposed Avere business combination.
- The proceeding could leave uncertainty regarding the validity of the 2025 reverse split, the company’s capitalization and shares or instruments issued in reliance on the amendment.
- Stockholders may appear at the November 6 hearing or submit written opposition by October 27, 2026, to the Register in Chancery, with a copy emailed to company counsel.
- NextCure stated that the Form 8-K and petition are not an offer or solicitation relating to the proposed Avere transaction. The company expects to file a Form S-4 containing a proxy statement/prospectus and urged investors to review it when available.
Important Facts to Verify
- Verify the status and outcome of the November 6, 2026 Section 205 hearing and any resulting court order.
- Confirm whether the 2025 reverse split and shares issued in reliance on it are ultimately validated.
- Review the proposed Avere transaction’s Form S-4, including transaction terms, capitalization effects, shareholder votes and closing conditions.
- Consult NextCure’s latest Form 10-K, Form 10-Q and subsequent filings for current financial condition, liquidity, financing needs and other risks not addressed in this 8-K.